Subscribe
shutterstock_1608793423_lev_radin
lev radin / Shutterstock.com
23 November 2021Biotechnology

Activists urge Biden to champion temporary COVID-19 IP waiver

Medical and human rights groups have called on US President Joe Biden to step up his personal engagement and help put in place a temporary waiver of IP rights for COVID-19 vaccines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
IP waiver won’t solve vaccine problems, warn experts
1 February 2022   A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization failing to reach consensus.
Big Pharma
Omicron variant delays COVID-19 IP waiver debate
29 November 2021   The World Trade Organization has postponed its ministerial conference indefinitely, potentially ending the opportunity for countries to agree an IP waiver for COVID-19 vaccines this year.
Americas
Former world leaders call on Biden to waive COVID IPs
15 April 2021   A group of more than 170 former world leaders and Nobel Laureates has called upon US President Joe Biden to waive IP rights for COVID vaccines, in an open letter posted yesterday.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

article
IP waiver won’t solve vaccine problems, warn experts
1 February 2022   A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization failing to reach consensus.
Big Pharma
Omicron variant delays COVID-19 IP waiver debate
29 November 2021   The World Trade Organization has postponed its ministerial conference indefinitely, potentially ending the opportunity for countries to agree an IP waiver for COVID-19 vaccines this year.
Americas
Former world leaders call on Biden to waive COVID IPs
15 April 2021   A group of more than 170 former world leaders and Nobel Laureates has called upon US President Joe Biden to waive IP rights for COVID vaccines, in an open letter posted yesterday.

More on this story

article
IP waiver won’t solve vaccine problems, warn experts
1 February 2022   A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization failing to reach consensus.
Big Pharma
Omicron variant delays COVID-19 IP waiver debate
29 November 2021   The World Trade Organization has postponed its ministerial conference indefinitely, potentially ending the opportunity for countries to agree an IP waiver for COVID-19 vaccines this year.
Americas
Former world leaders call on Biden to waive COVID IPs
15 April 2021   A group of more than 170 former world leaders and Nobel Laureates has called upon US President Joe Biden to waive IP rights for COVID vaccines, in an open letter posted yesterday.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB